Year All20242023202220212020 Date Title Apr 11, 2024 MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344 Apr 11, 2024 MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients Apr 10, 2024 MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum Mar 26, 2024 MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia Feb 13, 2024 MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights Jan 16, 2024 MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
